Skip to main content

Table 1 Model inputs

From: Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France

Clinical inputs for transition probabilities Values Sources
Baseline features     
Age distribution (mean in years) 70.5 Blotman et al. 2007 [7]
Prior fracture (%) 59.7  
Fracture probabilities     
Absolute risk by age (% per year) Vertebrae Hip Wrist  
50-54 years 3.10 0.00 2.99  
55-59 years 3.59 0.06 3.20  
60-64 years 4.15 0.20 3.18 Cotté et al. 2009 [24]
65-69 years 4.81 0.34 2.06  
70-74 years 5.56 0.65 1.97  
75-79 years 6.44 1.04 1.17  
80-84 years 7.45 1.62 0.92  
> 84 years 8.62 3.52 0.92  
Relative risk Vertebrae Hip Wrist  
associated with any prior fracture at baseline 2.0 2.0 1.9  
post-vertebral fracture health state 4.4 2.3 1.4 Klotzbuecher et al. 2000 [25]
post-hip fracture health state 2.5 2.3 NA  
post-wrist fracture health state 1.7 1.9 3.3  
Relative risk reduction with BP Vertebrae Hip Wrist  
for any women at baseline 0.526 0.672 0.833  
from post-vertebral fracture health state 0.575 0.620 NA Kanis et al. 2002 [9]
from post-hip fracture health state NA 0.620 NA  
from post-wrist fracture health state 0.575 0.620 0.566  
Loss of bisphosphonate protection     
Treatment duration (T; in months) Persistence rates (P; in %)  
Start 100 Fardellone et al. 2005 [28]
6 65 *Source data were fitted to an exponential function to generate persistence curve over 24 months:
12 51 P = 1 - 0.196 × ln(T)
24 41  
36 30*  
48 24*  
60 to simulation ending time 20*  
Treatment duration (T; in months) Protection duration** (y; in months)  
Start 0 Cotté et al. 2009 [39]
12 24 **Residual effect of BP was modeled as follow:
24 43 y = 13.5 × e0.048 × T
36 76  
48 All simulation period  
60 to simulation ending time All simulation period  
\